Loading...
Intas Pharmaceuticals Ltd — Busulfan Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #4 for Busulfan · $324.7K export value · DGFT Verified
Intas Pharmaceuticals Ltd is the #4 Indian exporter of Busulfan with $324.7K in export value and 16 verified shipments. Intas Pharmaceuticals Ltd holds a 6.6% market share in Busulfan exports across 5 countries.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $457.7K | 12 | 33.3% |
| UNITED KINGDOM | $202.7K | 10 | 14.7% |
| POLAND | $158.6K | 6 | 11.5% |
| PERU | $130.2K | 3 | 9.5% |
| NETHERLANDS | $99.7K | 15 | 7.3% |
| SOUTH AFRICA | $80.6K | 4 | 5.9% |
| BRAZIL | $66.0K | 3 | 4.8% |
| THAILAND | $65.5K | 4 | 4.8% |
| AUSTRALIA | $36.5K | 1 | 2.7% |
| SPAIN | $27.9K | 4 | 2.0% |
Intas Pharmaceuticals Ltd exports Busulfan to 15 countries. The largest destination is UNITED STATES accounting for 33.3% of Intas Pharmaceuticals Ltd's Busulfan shipments, followed by UNITED KINGDOM (14.7%) and POLAND (11.5%). These destinations reflect Intas Pharmaceuticals Ltd's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EVERSANA LIFE SCIENCES SERVICES,LLC | UNITED STATES | $179.8K | 6 |
| ACCORD UK | UNITED KINGDOM | $111.6K | 7 |
| ACCORD HEALTHCARE S.A.C. | PERU | $100.0K | 2 |
| MYLAN INSTITUTIONAL INC GSO | UNITED STATES | $100.0K | 2 |
| ACCORD HEALTHCARE POLSKA SP Z O O | POLAND | $100.0K | 2 |
| TO THE ORDER | UNITED KINGDOM | $93.4K | 2 |
India exported $4.7M worth of Busulfan through 369 shipments from 33 suppliers to 44 countries, serving 109 buyers globally. Intas Pharmaceuticals Ltd contributes $324.7K to this total, accounting for 6.6% of India's Busulfan exports. Intas Pharmaceuticals Ltd ships Busulfan to 15 countries through 35 buyers.
Intas Pharmaceuticals Ltd's average Busulfan shipment value is $20.3K per consignment, based on 16 shipments totaling $324.7K. The largest destination is UNITED STATES (33.3% of Intas Pharmaceuticals Ltd's Busulfan exports).
Intas Pharmaceuticals Ltd ranks #4 among 33 Indian Busulfan exporters with a 6.6% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($2.0M), EMCURE PHARMACEUTICALS LIMITED ($1.5M), FRESENIUS KABI ONCOLOGY LIMITED ($627.6K). Intas Pharmaceuticals Ltd processed 16 shipments to 5 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHA.DRU & MEDI, BUSULFAN INJECTION 6MG/M | $114.9K | 3 |
| PH.DRU. & MED.: BUFANCORD (BUSULFAN CONC | $100.0K | 2 |
| BUSULFAN INJ 6MG/ML 10ML 1X8V MYLAN USA | $100.0K | 2 |
| PHARMA DRUGS & MEDI BUSULFAN INJ,6MG/ML,10MLX1VACCORD-PL/RO AS PER DOCUMENT | $100.0K | 2 |
| PHARMA DRUG&MED:BUSULFAN INJ,6MG/ML,10ML | $98.6K | 8 |
| PHARMA DRUGS & MEDI BUSULFAN INJ,6MG/ML, | $66.6K | 8 |
| PHR DRUGS & MEDI ACCORAN BUSULFAN 6MG/ML | $59.9K | 2 |
| PHARMA DRUG&MED: BUSSULFANO 60MG/10ML,10ML 1V (AC-BR)EACH ML CONTAINS: BUSULFANPH.EUR. 6MG COLOUR N.A.VLS | $50.0K | 1 |
What Intas Pharmaceuticals Ltd must comply with to export Busulfan to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | EMCURE PHARMACEUTICALS LIMITED | $1.5M | 109 | 9 | $14.1K |
| 3 | FRESENIUS KABI ONCOLOGY LIMITED | $627.6K | 77 | 7 | $8.2K |
| 4 | INTAS PHARMACEUTICALS LTD ★ | $324.7K | 16 | 5 | $20.3K |
| 5 | SHILPA MEDICARE LIMITED | $150.5K | 5 | 4 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 75 | 20.3% |
| SAHAR AIR | 62 | 16.8% |
| DELHI AIR | 41 | 11.1% |
| DELHI AIR CARGO ACC (INDEL4) | 31 | 8.4% |
| AHEMDABAD AIR ACC (INAMD4) | 26 | 7.0% |
| AHEMDABAD AIR | 21 | 5.7% |
| MUNDRA SEA (INMUN1) | 17 | 4.6% |
| Ahmedabad Air | 13 | 3.5% |
Latest developments and market context
Detailed market intelligence for Busulfan — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Ltd's Busulfan exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
| EVERSANA LIFE SCIENCES SERVICES,LL |
| UNITED STATES |
| $80.4K |
| 2 |
| ACCORD FARMACEUTICA LTDA | BRAZIL | $66.0K | 3 |
| ACCORD HEALTHCARE C/O QESTMED (PTY) | SOUTH AFRICA | $59.9K | 2 |
| ACCORD HEALTHCARE THAILAND LTD | THAILAND | $58.6K | 2 |
Intas Pharmaceuticals Ltd supplies Busulfan to 35 buyers globally. The largest buyer is EVERSANA LIFE SCIENCES SERVICES,LLC (UNITED STATES), followed by ACCORD UK (UNITED KINGDOM) and ACCORD HEALTHCARE S.A.C. (PERU). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| PHA.DRU & MEDI BUSULFAN INJECTION6MG/ML10ML8V(ACC-US EACH ML CONTAINS BUSULFAN USP 6 MG 1239X1X8VIAL |
| $50.0K |
| 1 |
| PHARMA DRUGS AND MEDI BUSULFAN INJECTION6MG/ML,10ML8V(ACC-US) BUSULFAN USP 6 MG | $47.5K | 1 |
Intas Pharmaceuticals Ltd exports 64 distinct Busulfan formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHA.DRU & MEDI, BUSULFAN INJECTION 6MG/M with 3 shipments worth $114.9K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| $30.1K |
| 6 | SP ACCURE LABS PRIVATE LIMITED | $52.3K | 4 | 2 | $13.1K |
Intas Pharmaceuticals Ltd ranks #4 among 33 Indian Busulfan exporters. Average shipment value of $20.3K compared to the market average of $143.5K. The closest competitors by value are EMCURE PHARMACEUTICALS LIMITED and FRESENIUS KABI ONCOLOGY LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 44+ countries, 109+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Ltd.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Busulfan. For current shipment-level data, contact TransData Nexus.